These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 38560572)
21. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways. Chen SR; Cai WP; Dai XJ; Guo AS; Chen HP; Lin GS; Lin RS Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3461-3470. PubMed ID: 31081101 [TBL] [Abstract][Full Text] [Related]
22. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas. Ming Y; Luo C; Ji B; Cheng J BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267 [TBL] [Abstract][Full Text] [Related]
23. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. Liu J; Xu K; Ma L; Wang Y Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410 [TBL] [Abstract][Full Text] [Related]
24. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival. Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266 [TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma. Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479 [TBL] [Abstract][Full Text] [Related]
27. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas. Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G Front Immunol; 2022; 13():917014. PubMed ID: 35812432 [TBL] [Abstract][Full Text] [Related]
28. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma. Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194 [No Abstract] [Full Text] [Related]
29. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
30. miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. Jiang L; Wang C; Lei F; Zhang L; Zhang X; Liu A; Wu G; Zhu J; Song L Oncotarget; 2015 Apr; 6(10):8286-99. PubMed ID: 25823655 [TBL] [Abstract][Full Text] [Related]
31. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J Front Oncol; 2021; 11():611038. PubMed ID: 33937022 [TBL] [Abstract][Full Text] [Related]
32. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680 [TBL] [Abstract][Full Text] [Related]
33. IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms. Mei W; Dong Y; Gu Y; Kapoor A; Lin X; Su Y; Vega Neira S; Tang D J Adv Res; 2023 Dec; 54():195-210. PubMed ID: 36681115 [TBL] [Abstract][Full Text] [Related]
34. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas. Li JW; Huang QR; Mo LG Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129 [TBL] [Abstract][Full Text] [Related]
35. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas. Li J; Zhang Y; Qu Z; Ding R; Yin X Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373 [TBL] [Abstract][Full Text] [Related]
36. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer. Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Seo SP; Kang HW; Kim WT; Lee JY; Ryu DH; Choi JW; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ Clin Genitourin Cancer; 2019 Jun; 17(3):e704-e711. PubMed ID: 31088707 [TBL] [Abstract][Full Text] [Related]
37. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924 [TBL] [Abstract][Full Text] [Related]
38. MRPS23 is a novel prognostic biomarker and promotes glioma progression. Wang Q; Chen G; Liu L; Peng X; Yang X; Yang L; Li C Aging (Albany NY); 2024 Jan; 16(3):2457-2474. PubMed ID: 38301044 [TBL] [Abstract][Full Text] [Related]
39. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas. Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415 [TBL] [Abstract][Full Text] [Related]
40. Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells. Guo SK; Shen MF; Yao HW; Liu YS Cell Physiol Biochem; 2018; 49(3):1097-1109. PubMed ID: 30196284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]